In a preclinical study of anti-CD19 CAR-CD45RA negative cells, they significantly improved in vivo tumour suppression and survival compared to NT controls, while CAR-CD45RA+ cells achieved similar antileukaemic activity, but led to severe xenogeneic GVHD and death of all mice before D50 [87]. The gene discussed is CD19; the disease is neoplasm.